Annovis Bio, Inc.
ANVS
$2.60
-$0.10-3.70%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 38.86% | 56.25% | 1.86% | -28.67% | -59.34% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.49% | -87.77% | 168.94% | -15.58% | 18.31% |
| Change in Net Operating Assets | -161.34% | 398.08% | 72.48% | 445.32% | 206.73% |
| Cash from Operations | 35.09% | 45.22% | 32.85% | -1.09% | -36.49% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 93.36% | 53.89% | 240.99% | 102.99% | 293,845.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 93.36% | 53.89% | 240.99% | 102.99% | 293,845.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 240.21% | 121.21% | 124.51% | 42.09% | 47.43% |